{
    "title": "Novartis to pay $245 mln to end antitrust cases over Exforge drug generics",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11581123/Novartis-pay-245-mln-end-antitrust-cases-Exforge-drug-generics.html",
    "date": "2022-12-29",
    "keywords": [
        "exforge",
        "litigation",
        "novartis",
        "york",
        "par",
        "jonathan",
        "hypertension",
        "corp",
        "agreement",
        "generic",
        "court",
        "district",
        "dec",
        "ag",
        "wednesday",
        "drugmaker",
        "launch",
        "drug",
        "approval",
        "judge",
        "manhattan",
        "company",
        "matter",
        "health",
        "kroger",
        "co",
        "rite",
        "aid",
        "alliance",
        "classaction",
        "licensing",
        "plcs",
        "unit",
        "reverse",
        "payment",
        "blood",
        "pressure",
        "risk",
        "expiration",
        "exclusivity",
        "period",
        "market",
        "brandname",
        "case",
        "reporting",
        "stempel",
        "editing",
        "muralikumar",
        "anantharaman",
        "bradley",
        "perrett"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}